MedTrace Logo

Growth and Asymmetric diMethylArginine

NCT03422081 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2025-12-16

No results posted yet for this study

Summary

Principal objective : Validation of a handy biochemical parameter, plasma concentration of Asymmetric DimethylArginine (ADMA), based on a recognize biochemical parameter, the dilation of the brachial artery, at ultrasound examination, after the deflation of a cushion to evaluate artery dysfunction (vascular suffering) in growth diseases, growth hormone deficiency (GHD) and intrauterine growth retardation (IUGR)

Secondary objectives:

* Comparison of ADMA plasma concentrations with dose of matched healthy control children
* Investigation of the mechanisms of arterial dysfunction, inflammation, oxidative stress and insulin resistance.

Conditions

  • Growth Hormone Deficiency
  • Small-for-gestational Age

Interventions

DIAGNOSTIC_TEST

arterial doppler ultrasound

doppler ultrasound

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Jacques Weill, MD, PhD · University Hospital, Lille

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03422081 on ClinicalTrials.gov